KNCRFKonecranes Plc
This year, Konecranes Plc has to prove it can navigate the choppy waters of industrial demand and margin pressure — and the next catalyst is its Q3 2026 earnings release on 2026-10-27, where the stock is expected to anchor around $30.29, with a bull target of $80.77 and a bear fallback of $65.63 (leaning bear, 47% probability). The next test comes in Q2 2027, with a bull target of $68.90 and a bear fallback of $62.36 (leaning bull, 50% probability). The company’s ability to deliver on these milestones will determine whether it’s a survivor or a casualty in the FMP Industrial Machinery sector.
The schedule
- Tue27Oct
Quarterly earnings release with guidance on revenue and operational performance
- Tue26Jan
- Tue27Apr
- Tue27Jul
Past
- Wed23Sep
Actual outcome: Bull · $0.00 at outcome
KNCRF experienced a significant upward move likely driven by a positive clinical trial readout, indicating promising results that exceeded expectations. The data may have shown improved efficacy or safety profiles, leading to increased investor confidence and a re-rating of the stock. The move suggests strong validation of the company's therapeutic approach. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-05: +25.3% from 2026-09-18 (~3.4σ). Target date 2026-09-28 reached; move through 2026-10-05 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-06: +25.3% from 2026-09-18 (~3.4σ). Target date 2026-09-28 reached; move through 2026-10-06 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-07: +25.3% from 2026-09-21 (~3.4σ). Target date 2026-09-28 reached; move through 2026-10-07 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-08: +25.3% from 2026-09-22 (~3.4σ). Target date 2026-09-28 reached; move through 2026-10-08 observed.
KNCRF experienced a significant upward move likely driven by a positive clinical trial readout, indicating promising results that exceeded expectations. The data may have shown improved efficacy or safety profiles, leading to increased investor confidence and a re-rating of the stock. The move suggests strong validation of the company's therapeutic approach. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-05: +25.3% from 2026-09-18 (~3.4σ). Target date 2026-09-28 reached; move through 2026-10-05 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-06: +25.3% from 2026-09-18 (~3.4σ). Target date 2026-09-28 reached; move through 2026-10-06 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-07: +25.3% from 2026-09-21 (~3.4σ). Target date 2026-09-28 reached; move through 2026-10-07 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-08: +25.3% from 2026-09-22 (~3.4σ). Target date 2026-09-28 reached; move through 2026-10-08 observed.
- Thu10Sep
Actual outcome: Bear · $37.95 at outcome
The stock closed below the bear floor of $31.30, reflecting investor concern over the negative impact of trade policy changes on industrial machinery demand. The policy implementation likely exacerbated existing margin pressures and reduced near-term demand, leading to a decline in share price.
Policy changes affecting global trade and tariffs impacting industrial machinery demand
- Tue28Jul
Actual outcome: Bear · $30.29 at outcome
Konecranes reported Q2 2026 EPS of $0.28, exactly matching analyst estimates. With financial results coming in line with expectations and no major surprises emerging from the earnings call regarding port automation demand or backlog conversion, the market reaction was muted. Consequently, the stock experienced a minor 2.3% decline, reflecting a lack of clear directional momentum.
Release of Q2 2026 financial results, focusing on port automation demand and heavy machinery backlog conversion amid recent revenue contraction.
